Immuron Ltd — Regulatory Filings 2011

Aug 28, 2011

==> picture [54 x 33] intentionally omitted <==

==> picture [55 x 33] intentionally omitted <==

==> picture [54 x 33] intentionally omitted <==

IMMURON’S NOVEL INFLUENZA PRODUCT ADVANCES TO HUMAN TRIAL

• Oral preventative/immune boosting product to proceed to a Phase 1/2a clinical trial

• Board provides go-ahead based on encouraging animal studies  Aiming for commercial ready product in two years

Melbourne, Australia, Monday 29 August 2011: Australian biopha r maceutical compa n y Immuron [ASX: IM C ] will soon c ommence Phase 1/2 a human tri a ls for its influen z a product, IMM 255.

Animal studies in m ice and fe r rets conducted in Israel and Aus t ralia conti n ue to supp o rt the use of Immuron’s o ral prepar a tion again s t influenza viruses. B a sed on th e se results Immur o n’s Board h as commit t ed to proc e ed with human trials, expected t o commence this calend a r year.

We anticipate that a placebo- c ontrolled, P hase 1/2a study will b e conduct e d at Hada s sah Medica l Center in J erusalem u sing healt h y volunteers. The ai m of the stu d y is to me a sure the ext e nt to whic h Immuron’ s product w i ll boost im m unity against influen z a virus.

“We be l ieve that w e are en-route to dev e loping a u n ique produ c t with ben e fits that h a ve global p ossibilities , especially in light of t h e human a nd econo m ic burden s of influenza. If all progre s ses according to expectations w e anticipate having a c o mmercial- r eady prod u ct as early a s two years after com m encing thi s trial,” said Joe Baini, Immuron’s C hief Executive Officer.

Profes s or Yaron Il a n, Head o f the Depar t ment of M e dicine at Hadassah M edical Cen t er, Jerusal e m stated: “One of th e key advantages of I m muron’s pr o duct is th a t, unlike current flu vac c ines, it appears to bo o st the imm u ne syste m regardles s of the strain of influe n za.”

Contact Joe Baini – Chief E xecutive O fficer Rudi Mich e lson +61 3 8637 1107 Monsoon C ommunica t ions +61 3 962 0 3333 0411 402 7 37

About Immuron Limited

Immur o n is a biop h armaceuti c al company focused o n oral immunotherap y using dair y - derived antibody products for humans. I m muron is a uniquely p ositioned b iotechnolo g y compa n y with a v e rsatile technology plat f orm capa b le of gener a ting a wid e range of products with a hi g h safety pr o file. This h igh safety profile ma k es it possi b le to complete pre-clinical studies relatively q uickly and increases the prospect that the clinical develo p ment of Immuron’s pr o ducts will b e expedit e d. Immuron’s current products a n d product candidate s target inf e ctious dise a ses of the gastrointe s tinal tract, c hronic dis e ases such a s fatty liver ( NASH), and the prev e ntion of inf l uenza. Im m uron has o ne produ c t in the ma r ket, Travel a n, for preventing trav e llers’ diarr h oea. Immur o n’s main s c ientific alli a nces are w ith Hadassah Medical Center (Is r ael), the Univer s ity of Melb o urne and M onash Un i versity (Au s tralia).